Dominique Duterte-Boucher

In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion

We compared the ability of various dopamine (DA) uptake inhibitors to displace the in vivo striatal [3H]GBR 12783 (1-[2(diphenylmethoxy) ethyl)-4-(3-phenyl-1[3H]-2-propenyl)-piperazine) binding with their stimulant effect on locomotor activity on mice. GBR 12783 (8 mg/kg), GBR 13069 (10 mg/kg), cocaine (20 mg/kg), mazindol (3 mg/kg) or pyrovalerone (2 mg/kg) stimulated locomotion as long as they occupied the DA uptake complex. In contrast, nomifensine (3 mg/kg) did not stimulate locomotion although it competed with [3H]GBR 12783 for the occupancy of the DA uptake complex at a significant level (> 50%). Administered at their ED50 doses, GBR 12783, BTCP (N-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine, GBR 13069, amineptine and dexamphetamine significantly increased locomotor activity whereas the other inhibitors tested did not. The locomotor response elicited by GBR 12783 (10 mg/kg) was not decreased by desipramine (20 mg/kg) nor by oxaprotiline (10 mg/kg). The increase in locomotion elicited by GBR 12783 was positively correlated with the basal locomotor activity of the mice. The stimulant effect of GBR 12783 was potentiated by SKF 525A and by budipine. Additional pharmacological properties might conceal the relationship between the effects of some DA uptake inhibitors on locomotion, and on in vivo occupancy of DA uptake sites.

Anxiety increases the place conditioning induced by cocaine in rats

Some clinical studies have shown that anxiety disorders are often associated with drug dependence, although it remains unclear whether these disorders are primary or secondary to drug abuse. We have investigated whether anxiety may be a factor that predisposes to cocaine use. From an outbred Wistar strain, we have selected male rats regarded as anxious or non-anxious on the basis of their scores on two behavioural tests of unconditioned anxiety, the elevated plus-maze and the light/dark box test. They were also screened for their locomotor activity in an inescapable novel environment and for their preference for novelty presented in a free-choice. Rewarding effects of cocaine (2.5-20 mg/kg; i.p.) were then determined in the conditioned place preference paradigm (CPP). Anxious and non-anxious rats showed no difference in their responsiveness to inescapable novelty or their preference for novelty in a free-choice procedure. Only anxious rats developed a CPP induced by increasing doses of cocaine, the magnitude of CPP induced by the 10 mg/kg dose of cocaine being significantly higher than that observed in anxious rats conditioned with saline. These results suggest that anxiety affects the sensitivity to aversive/anxiogenic effects of cocaine. Thus, anxious rats which were highly responsive to positive effects of cocaine may be more prone to develop cocaine addiction than non-anxious rats.

Modulation of morphine and alcohol motor stimulant effects by cannabinoid receptors ligands.

Previous studies evidenced in rats the suppression by cannabinoids of motor stimulant effects of various drugs of abuse. Here we investigated, in mice, the effects of an acute or a chronic administration with the cannabinoid agonist HU 210 on the motor stimulant effects of either morphine or alcohol. HU 210 (12.5-200 microg/kg), when acutely administered, antagonized the stimulant effects of morphine (7.5 mg/kg) or alcohol (1 or 1.5 g/kg). A tolerance to this antagonistic interaction with morphine and alcohol occurred after a 7-day or a 14-day HU 210 treatment, leading to the reappearance of morphine- and alcohol-induced stimulation. The CB1 receptor antagonist rimonabant (10 mg/kg) enhanced the stimulant effect induced by low doses of morphine (5 or 7.5 mg/kg). Rimonabant (3 or 10 mg/kg) altered the locomotor effect of alcohol in a biphasic manner. It enhanced the stimulant effect of low doses of alcohol (1 or 1.5 g/kg) while decreasing the locomotor activity of mice treated with a high dose (3 g/kg) of alcohol. Furthermore, rimonabant (3 and 10 mg/kg) enhanced the duration of alcohol-induced loss of righting reflex (4 g/kg), suggesting a dual implication of cannabinoidergic pathways in acute effects of alcohol.

Locomotor sensitization to [d-Trp11]neurotensin after repeated injections of the dopamine uptake inhibitor GBR12783 in rats

Rats received one daily i.p. injection of the dopamine uptake inhibitor GBR12783 (1-[2-(diphenylmethoxy)ethyl]4-(3-phenyl-2-(propenyl)-piperazine) (10mg/kg) or vehicle for 9 days. Fourteen days after discontinuing treatment, their locomotor activity was assessed after injection of GBR12783 (5 mg/kg) or vehicle, then 6 days later, after i.c.v. injection of [D-Trp(11)]neurotensin (750 ng) or saline. A sensitization to the stimulant locomotor effects of both GBR12783 and [D-Trp(11)]neurotensin occurred in rats exposed to the actimeter following the 1st, 5th and 9th injections of GBR12783. Rats without prior experience of the activity cages before the challenge tests showed no sensitization to either GBR12783 or [D-Trp(11)] neurotensin. Our data suggest that a similar mechanism may underlie the locomotor sensitization to GBR12783 and the heterosensitization to [D-Trp(11)]neurotensin.

Appearance of a stereotyped apomorphine-induced climbing in unresponsive DBA2 mice after subchronic manipulations of brain dopamine transmission.

DBA2 mice show an erratic spontaneous climbing which is reduced by increasing doses of direct dopamine agonists (apomorphine up to 5 mg/kg, piribedil up to 20 mg/kg). Sustained stereotyped climbing occurs when animals are treated with l-dopa plus benserazide and dexamphetamine. In this strain, which is spontaneously insensitive to apomorphine-induced climbing, this behaviour progressively appeared in a stereotyped manner after repeated administrations of apomorphine (5 mg/kg). The sensitization to apomorphine-induced climbing is long-lasting (more than 15 days). A similar sensitization may be induced by repeated administrations of either piribedil or of the dopamine uptake inhibitor GBR 12783. The semichronic reduction in dopaminergic transmission induced by four administrations of haloperidol (2 mg/kg at 2-day intervals) or by pretreatment with reserpine (3 mg/kg) induced sensitization to apomorphine-induced climbing. These results are discussed in terms of modifications in the sensitivity of two types of dopamine receptors exerting opposite effects on climbing behaviour.

Invariance of the density of dopamine uptake sites and dopamine metabolism in the rat brain after a chronic treatment with the dopamine uptake inhibitor GBR 12783

A chronic treatment (10 mg/kg, twice daily during 9 days) with the dopamine uptake inhibitor GBR 12783 was performed in rats at a dose increasing their locomotor activity. Forty-eight hours after the last administration, animals were sacrificed and3H mazindol binding was performed on brain slices. Autoradiographic analysis revealed no change in this binding relatively to control animals in regions with high dopamine contents: striatum, nucleus accumbens, olfactory tubercle, substantia nigra and ventral tegmentum area. The treatment did not either modify the levels of dopamine (DA) and metabolites (HVA, DOPAC) both in the striatum and the nucleus accumbens. Thus, early after the end of the treatment, the chronic blockade of the dopamine uptake complex regulates neither the dopamine uptake complex nor the dopamine metabolism.

Locomotor effects of morphine or alcohol in mice after a repeated treatment with the cannabinoid agonist HU 210

The consequences of the consumption of cannabinoids with other drugs of abuse are of particular medical relevance. Several studies investigated the ability of cannabinoids to induce a locomotor cross-sensitization to other addictive drugs, but results remain inconsistent. Therefore, we investigated in mice the consequences of a repeated treatment with the cannabinoid agonist HU 210 on motor effects of morphine or alcohol. In mice receiving a daily injection of HU 210 (12.5 to 200 microg/kg) during 7 days, no hetero-sensitization to the stimulation induced by either morphine (7.5 mg/kg) or alcohol (1 or 1.5 g/kg) emerged, from 1 day up to 35 days after the end of the sub-chronic treatment with HU 210. Even a chronic treatment with a high dose of HU 210 (14 days, 200 microg/kg) induced no subsequent enhancement of the stimulant effects of morphine or alcohol. In fact, the motor stimulant effect of morphine or alcohol in chronically HU 210 pre-treated mice was even abolished until the 3rd day of abstinence. This reduction was presumably due to residual HU 210 since this effect was prevented by the cannabinoid antagonist rimonabant. Afterwards, chronically cannabinoid pre-treated mice remained less active than vehicle pre-treated mice from the 7th day up to the 35th day after the end of the 14-day treatment with HU 210. In conclusion, we failed to detect any hetero-sensitization whatever the pre-treatment regimen. However, only after the 14-day regimen, HU 210 pre-treated mice displayed a long-lasting decrease in activity, suggesting that some neuronal adaptive changes may have occurred.